Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Review 2019: US witnesses bumper year of veterinary approvals, while EU achieves milestone authorizations
In 2019, both the US and Europe saw several significant approvals in animal health. Animal Pharm analyst Sian Lazell gives an overview of the most notable products that were given the green light for their commercial debuts during the year.
Subscribers have five weeks to nominate their company and innovations as part of the Animal Pharm Awards for 2019.
US firm Mizner Bioscience has received US FDA approval for the first generic form of clomipramine hydrochloride tablets.
Veterinary generics account for around €2.9 billion ($3.17 billion) in sales in Europe, according to a new study.
Bulgarian firm Huvepharma has opened a new fermentation plant in the south of the country.
Elanco has said it is prepared for off-patent competition, after Huvepharma was recently given the green light by the US FDA for the first generic monensin for certain indications in cattle and goats.
Bimeda Animal Health has received US approval for generic injectable treatments for swine and cattle.
US pet medication developer and distributor PetIQ believes it can help recent acquisition Perrigo Animal Health return to annual growth.
European authorities have paved the way for Virbac to gain authorization of Evicto – a generic antiparasitic for cats and dogs.
Dutch company Curados has signed a worldwide exclusive agreement with TBD-Biodiscovery for the development and synthesis of five active pharmaceutical ingredients (APIs) in the animal health space.
Florida-based Modern Veterinary Therapeutics (MVT) has launched its generic Medetomidine Hydrochloride injection (1mg/ml) in the US.
PetIQ is to acquire veterinary generics specialist Perrigo Animal Health – a deal that underlines the growing importance of a multi-channel approach to selling companion animal drugs.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.